Prescription Medicine Pricing: Advancing Responsible Leadership
At Sanofi, we have a longstanding commitment to fostering healthcare systems that make our treatments accessible and affordable to those in need.
Our Pricing Principles detail how we price our medicines and advocate for policy solutions to make the system work better for patients and their care teams. By publishing results over the past decade, we aim to build transparency and enable a more informed U.S. dialogue on medicine pricing.
The Three Pillars of Our Pricing Principles
Clear Rationale for Pricing:
We take a holistic approach to pricing new medicines, considering patient perspectives, clinical value compared to existing treatments, economic impact on overall healthcare costs, social contributions to quality of life, and system-wide affordability.
Reporting of U.S. Pricing Actions:
We balance innovation and responsibility to help contain healthcare spending. We adhere to responsible pricing principles for list price adjustments and annually disclose any mandatory supplemental rebates triggered by those actions.
Continued Transparency in the U.S.:
We annually disclose our average aggregate U.S. list and net price changes to foster better-informed discussions about patient access and affordability.
Featured Brief
NEW Prior Authorization: How Targeted Reforms Can Protect Patient Access
Prior authorization is recognized as one of the biggest burdens for patients when it comes to accessing tests, treatments, or medications. Targeted reforms can protect patient access.
Our Perspectives on Proposed Policy Solutions

NEW Step Therapy: How “Fail First” Can Fail Patients

Unlocking New Potential for Existing Medicines
A Closer Look at 340B
Navigating the Complexities of Accessing Specialty Medicine
Health Policy Solutions Protecting Innovation
Explore more

Patient Support

June 29, 2026
Putting Patients First by Reining In Prior Authorization and Step Therapy

March 3, 2026
Navigating U.S. Policy: How Data and Transparency Guide Our Efforts

November 22, 2024
Sanofi Tackles 340B Abuse with Innovative Credit Model
MAT-US-2017357-v12.0-06/2026
